

MEDINEX LIMITED

Incorporated in the Republic of Singapore

Registration No. 200900689W

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

The Board of Directors (the "**Board**") of Medinex Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce the following transaction that occurred during the financial period from 1 October 2025 to 31 March 2026, pursuant to Rule 706A of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist:

Disposal of Express Medical Pte Ltd

The Company had, on 31 March 2026, entered into a sale and purchase agreement (the "**SPA**") to dispose of 55% of the total equity interest in Express Medical Pte Ltd ("**EM**" or the "**Target Company**") (the "**Disposal**") to Kainos Management Consultancy Pte Ltd (the "**Purchaser**"). EM has since ceased to be a subsidiary of the Company.

The aggregate consideration for the Disposal of 55% equity interest in the Target Company is S\$100,000.00 (the "**Sale Consideration**"), which was fully satisfied in cash, comprising a deposit of S\$10,000.00 paid by the Purchaser upon signing of the term sheet dated 13 March 2026, and the remaining balance of S\$90,000.00 paid in full as at the completion date of the Disposal.

The Sale Consideration was arrived at on a willing-buyer and willing-seller basis, following arm's length negotiations between the parties, taking into account the financial position of the Target Company as at 31 January 2026. The net asset value of the Target Company as at 31 January 2026 was S\$13,305.16, of which the net asset value attributable to 55% equity interest of the Target Company was S\$7,317.84. No independent valuation was conducted.

None of the Directors or substantial shareholders of the Company has any interest, direct or indirect, in any of the above transactions other than through their respective shareholdings in the Company.

By Order of the Board

Jessie Low Mui Choo

Executive Director and Chief Executive Officer

19 May 2026

This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.